AMGN vs. BMY: Amgen vs. Bristol-Myers Squibb Stock Comparison

Company Profile

Amgen (AMGN) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while BMY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Amgen (AMGN) at 78.35% and Bristol-Myers Squibb (BMY) at 44.01% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Amgen (AMGN) at 24.14% and Bristol-Myers Squibb (BMY) at 18.47% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Amgen (AMGN) at 35.79% and Bristol-Myers Squibb (BMY) at 33.79% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and Bristol-Myers Squibb (BMY) at -0.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Amgen (AMGN) at 1.48 and Bristol-Myers Squibb (BMY) at 1.59 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Debt sits unusually high against shareholders’ equity for both Amgen (AMGN) at 3.76 and Bristol-Myers Squibb (BMY) at 1.91 — each debt-to-equity ratio is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Amgen (AMGN) at 2.16% and Bristol-Myers Squibb (BMY) at 3.99% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Amgen (AMGN) at 57.62% and Bristol-Myers Squibb (BMY) at 55.88% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Amgen (AMGN) at 26.69 and Bristol-Myers Squibb (BMY) at 13.78 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Amgen (AMGN) at 6.40 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Bristol-Myers Squibb (BMY) at 5.43 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

Valuation Metrics